Devices for the management of ventricular arrhythmias in cardiac failure.
Heart failure is a common clinical syndrome with a high morbidity and mortality. Despite advances in medical treatment, death from dangerous ventricular arrhythmias is frequently implicated. Emerging evidence supports the use of the implantable cardioverter defibrillator for selected patients. This includes secondary prevention indications for patients who have survived life-threatening ventricular arrhythmias. In addition, patients who have not suffered spontaneous sustained ventricular arrhythmias, but who are at high risk for sudden arrhythmic death are starting to be recognized as candidates for ICD therapy. At present the only primary prevention indication with a good evidence base is the presence of inducible ventricular arrhythmias at electrophysiologic testing in patients with prior myocardial infarction, impaired left ventricular systolic function and non-sustained ventricular tachycardia on Holter monitoring. Studies planned or in progress are likely to expand further the role of device therapy in the treatment of patients with cardiac failure.
Cooklin
Michael
M
Department of Cardiology, King's College Hospital, London, UK.
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000628:therapy*; D002986:Clinical Trials as Topic; D016757:Death, Sudden, Cardiac / Q000517:prevention & control; D017147:Defibrillators, Implantable; D005260:Female; D006333:Heart Failure / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017180:Tachycardia, Ventricular / Q000209:etiology / Q000628:therapy